

# Author Correction: Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience

L. MONZO, C. GAUDIO, F. CICOGLA, C. TOTA, V. PETRONILLI,  
S. MENNUNI, E. DE RUVO, L. CALÒ

Department of Cardiology, Policlinico Casilino, Rome, Italy

Correction to: European Review for Medical and Pharmacological Sciences 2021; 25 (18): 5690-5700–DOI: 10.26355/eurrev\_202109\_26788–PMID: 34604961, published online on 30 September 2021.

After publication, the authors applied to change the first two lines of Table II as the second column results were erroneously shifted in the first column. In this way, the results were quite difficult to understand.

The Publisher apologizes for any inconvenience this may cause.

The corrected table is reproduced below.

**Table II.** Variables associated with left ventricular ejection fraction (LVEF) change.

Parameter	Correlation coefficient [95% CI]	p-value
Age, years	-0.185 [-0.446; 0.103]	0.206
Sex, male	0.108 [-0.181; 0.380]	0.464
Body surface area, m <sup>2</sup>	-0.142 [-0.418; 0.157]	0.349
NYHA class, II vs. III	0.321 [0.041; 0.555]	0.025
Systolic blood pressure, mmHg	0.076 [-0.212; 0.353]	0.604
HF aetiology, ischemic vs. non-ischemic	-0.072 [-0.349; 0.216]	0.626
Diabetes mellitus, (Yes vs. No)	0.136 [-0.153; 0.404]	0.355
Hypertension, (Yes c No)	-0.113 [-0.385; 0.176]	0.443
Atrial fibrillation, (Yes vs. No)	0.121 [-0.168; 0.392]	0.409
Potassium, mmol/L	-0.014 [-0.361; 0.335]	0.936
eGFR, mL/min/1.73 m <sup>2</sup>	0.197 [-0.101; 0.464]	0.193
NTproBNP, ng/L	0.202 [-0.139; 0.502]	0.243
LVEDVI, mL/m <sup>2</sup>	-0.439 [-0.837; 0.263]	0.204
LVESVI, mL/m <sup>2</sup>	-0.436 [-0.836; 0.266]	0.207
Baseline LVEF, %	-0.034 [-0.315; 0.252]	0.817
LV mass index, gr/m <sup>2</sup>	-0.079 [-0.374; 0.230]	0.617
MRA, (Yes vs.No)	-0.062 [-0.340; 0.226]	0.675
ACEi/ARB therapy duration, months	-0.103 [-0.422; 0.238]	0.554
Sacubitril/valsartan dose, >24/26 mg bid	0.364 [0.089; 0.587]	0.011

*Abbreviations:* ACEi – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blockers; bid – bis in die; eGFR – estimated glomerular filtration rate; MRA – mineralocorticoid receptor antagonist; NTproBNP - N-terminal pro b-type natriuretic peptide; NYHA – New York Heart Association; LV – left ventricular; LVEDVI – left ventricular end-diastolic volume index; LVESVI – left ventricular end-systolic volume index.